Europe Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Molecular, Conventional), By Infection Type (UTI, Pneumonia), By Product (Consumables, Instruments), By Type, By Country, And Segment Forecasts, 2025

Europe Hospital Acquired Infections Diagnostics Market Growth & Trends

The Europe hospital acquired infections diagnostics market size is anticipated to reach USD 1.61 billion by 2030, growing at a CAGR of 1.2% during the forecast period, according to a new report by Grand View Research, Inc. In recent years, the prevalence of infections, particularly sepsis and surgical site infections, has driven a surge in demand for effective diagnostic solutions. In Europe, approximately 3.4 million sepsis cases occurred annually, leading to nearly 700,000 deaths each year, highlighting the urgent need for advanced diagnostic tools. The rising incidence of bloodstream infections (BSIs) compelled healthcare providers to implement robust diagnostic measures, presenting substantial market opportunities for companies specializing in hospital-acquired infection (HAI) diagnostics.

Technological advancements significantly contributed to market growth, with innovations in molecular diagnostics and rapid testing methods enhancing the accuracy and speed of HAI detection. These developments allowed for more timely identification, ultimately improving patient outcomes.

In addition, increasing healthcare expenditure across European countries facilitated the adoption of HAI diagnostics. Investments in healthcare infrastructure and proactive government initiatives aimed at infection control fostered a supportive environment for market expansion. Heightened patient awareness regarding HAIs further amplified the demand for effective diagnostic solutions, as informed patients and healthcare providers alike sought timely diagnostics, propelling market growth for innovative diagnostic products.

Europe Hospital Acquired Infections Diagnostics Market Report Highlights

• Based on test type, the conventional tests dominated the market in 2024. Molecular tests, especially PCR-based methods, are projected to achieve the fastest CAGR of 1.5% during the forecast period, becoming essential for diagnosing hospital-acquired infections in Europe.
• Based on infection type, the UTI segment led the Europe hospital acquired infections diagnostics industry in 2024, accounting for a revenue share of 21.6% in 2024.
• In 2024, the consumables product segment captured the highest market share, driven by the need for accurate diagnosis, regulatory compliance, and high testing volumes in European hospitals.
• Based on type, the urinalysis segment is expected to grow lucratively due to rising UTI rates in hospitals, particularly in urology units, driven by high catheterization and demand for effective diagnostics.
• Key players operating in the market include BIOMÉRIEUX; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthineers AG; BD; HC Bioscience; QIAGEN; Thermo Fisher Scientific Inc.; Meridian Bioscience, Inc.; Hologic, Inc.
• In January 2025, BioMerieux announced its intent to pursue acquisitions with EUR 3bn- EUR 4bn available, enhancing its core segments within the diagnostics market.